Cartesian Growth Corporation III (CGCT) Company Overview

What did Cartesian Growth Corporation III actually do?

Cartesian Growth Corporation III was a Nasdaq-listed special purpose acquisition company, or SPAC, formed in October 2024 and sponsored by an affiliate of Cartesian Capital Group. It raised public cash, protected most of it in trust, and searched for a private company that could enter public markets through a merger. The sponsor described CGC3 as offering merger partners capital and operating expertise; the official CGC3 overview captures that mandate.

Why was CGCT different from an operating company?

A SPAC balance sheet is dominated by trust assets and redemption obligations, not customers, inventory, or recurring sales. CGCT had no commercial revenue; its assets were primarily trust investments while management evaluated a transaction. The 2025 Form 10-K is best read as a capital-structure and transaction document, not as a conventional corporate annual report.

How did CGCT make money before the merger?

CGCT’s earnings came almost entirely from interest on IPO proceeds held in trust. In May 2025, it sold 27.6 million units at $10.00 for $276.0 million. Each unit contained one Class A share and one-half warrant; a whole warrant had an $11.50 exercise price. It also sold 6.8 million private warrants at $1.00 each.

How did the trust account shape economics?

At December 31, 2025, trust investments were $283.377 million, including $7.377 million of accumulated interest. CGCT reported $6.219 million of net income against $1.158 million of general and administrative expense, but the profit reflected trust interest rather than customer demand or operating margin.

What did CGCT’s latest standalone financials show?

In the final standalone quarter ended March 31, 2026, trust investments reached $285.869 million, including $9.869 million of cumulative interest. CGCT earned $2.492 million of quarterly interest, incurred $0.811 million of general and administrative expense, and reported $1.680 million of net income, or $0.05 per share. The March 2026 Form 10-Q also showed how little liquidity was available outside the trust.

Why was positive net income not operating profitability?

Operating loss was $0.811 million because CGCT had no revenue. Interest produced accounting profit, while operating cash use was $0.228 million. Working capital was negative $0.878 million, current liabilities were $1.387 million, and the deferred underwriting fee was $13.140 million. Redeemable public shares were carried at about $286.047 million, or $10.36 per share, outside permanent equity.

Why did CGCT choose Factorial Energy?

The transaction shifted the investment case from protected cash to technology commercialization. Factorial develops solid-state batteries for vehicles, drones, robots, storage, and critical applications. FEST targets higher energy density and safety with processes compatible with much conventional lithium-ion equipment; Solstice is a sulfide-based all-solid-state architecture.

What evidence supported the strategic fit?

Factorial entered public markets with relationships involving Mercedes-Benz, Stellantis, Hyundai and Kia, PowerCo, and IQT. A modified Mercedes-Benz EQS reportedly completed a 1,205-kilometer road test with Factorial cells in 2025, while Stellantis tested 77 Ah cells. These milestones move evidence beyond laboratory claims toward pack integration and road use. The official transaction presentation framed the merger around validation-to-scale rather than immediate revenue.

How is the future revenue model expected to work?

Factorial was pre-revenue at March 31, 2026. Joint development agreements were collaborative arrangements, not ASC 606 customer contracts, so reimbursements reduced R&D rather than creating sales. The prospective model combines engineering, cell supply, licensing, and partner manufacturing. Early volumes can use U.S. and South Korean lines, while partners are expected to support large-scale production.

What does Factorial’s latest quarter reveal?

Factorial’s quarter ended March 31, 2026 showed no commercial revenue. Cash was $25.449 million versus $28.891 million at year-end 2025. Assets were $62.391 million, including $20.206 million of property and equipment. Liabilities were $41.382 million, including $24.896 million of convertible notes that converted at the merger.

Why did R&D expense fall without commercialization?

Net R&D expense fell to $1.942 million in Q1 2026 from $6.754 million a year earlier; SG&A fell to $4.549 million from $6.368 million. Factorial recorded $3.410 million of collaboration reimbursements against R&D, versus $0.034 million in Q1 2025, with one partner contributing $3.360 million. The Q1 2026 financial statements make clear that these payments were reimbursements, not revenue.

How much runway did the transaction create?

At closing, the successor received approximately $112.1 million of gross proceeds, including $100.9 million from PIPE investors. Pro forma transaction costs were about $18.3 million, and the pro forma combined cash balance was $118.808 million. Management estimated that resources could fund operations and planned capex into Q1 2028, subject to assumptions. The official Q1 2026 management discussion is the clearest source for that runway statement.

Which turning points shaped the CGCT-to-FAC story?

Each event changed protected capital, shareholder risk, or Factorial’s path to commercialization.

1. October 2024
   Cartesian Growth Corporation III was incorporated as a Cayman Islands blank-check company, creating the legal shell and sponsor structure.
2. May 2025
   The IPO raised $276.0 million from 27.6 million units, establishing the trust account and a 24-month acquisition deadline.
3. August–September 2025
   Factorial expanded OEM validation work, including a modified Mercedes-Benz EQS road test reported at 1,205 kilometers.
4. December 2025
   CGCT and Factorial signed the business combination agreement, shifting the story from target search to transaction execution.
5. February 2026
   Factorial entered a 15-month development agreement with PowerCo, adding another industrial-validation pathway.
6. May 27, 2026
   CGCT shareholders approved the combination; 23.051 million public shares ultimately redeemed, sharply reducing trust cash delivered.
7. June 5–8, 2026
   The merger closed, CGCT became Factorial Energy Inc., and the successor began Nasdaq trading under FAC and FACWW.

What did the closing change economically?

The closing converted a trust vehicle into a pre-revenue technology company. Of 27.6 million public shares, 23.051 million were redeemed at about $10.4159 each, or $240.1 million in aggregate. The 83.5% redemption rate left 4.549 million public shares, making the $100.9 million PIPE central to the $112.1 million gross proceeds. The closing Form 8-K documents the redemption, share issuance, financing, governance, and successor-ticker changes.

What gives Factorial a competitive position?

Factorial’s differentiators are large-format technical progress, global automotive relationships, and a manufacturing strategy intended to reduce scaling capital. The moat is unproven because recurring revenue, durable unit economics, and high-volume yields have not yet been demonstrated.

Which moat elements are tangible today?

Tangible resources include FEST and Solstice know-how, U.S. and South Korean fabrication capacity, OEM relationships, 14 issued U.S. patents, 47 pending or allowed U.S. applications, and 110 foreign or international patents and applications across nine jurisdictions at year-end 2025. Durability depends on enforceability, manufacturing performance, and customer adoption.

Where does competitive pressure come from?

Factorial competes with large cell incumbents, improving lithium-ion chemistries, and rival solid-state architectures. Incumbents have scale, supply leverage, and factory funding that Factorial cannot match alone. Its response is differentiation plus partner-supported manufacturing. The current Factorial registration statement emphasizes that larger competitors may have substantially greater resources and that conventional battery technology may remain cheaper.

Who owns and controls the successor company?

Post-closing capitalization comprised 91.511 million Series A and 15.513 million Series B shares, totaling 107.023 million. Founders Siyu Huang and Alex Yu held all Series B shares, alongside strategic, venture, and former SPAC owners.

Why do strategic owners matter?

Mercedes-Benz and Stellantis each owned 8.670 million shares, or 8.1%, while WAVE held 11.474 million, or 10.7%. Sponsor-related interests held 8.460 million, or 7.9%. Strategic concentration can provide capital and industry access, but related commercial and governance relationships require scrutiny.

How does governance affect interpretation?

Factorial began public life with a seven-member classified board and sizable equity incentives. The 2026 incentive plan reserved 21.0 million shares and the employee purchase plan 1.830 million. Options, RSUs, warrants, and future grants make the fully diluted share count essential.

What opportunities could change the growth trajectory?

The largest opportunity is converting development relationships into production programs. Automotive design wins can be durable after qualification and tooling, while drones and robotics may offer smaller, earlier markets willing to pay for energy density, lower weight, or safety.

Why does capital-light scaling matter?

Factorial expected about $7.5 million of remaining capital spending through 2026, with expansion completion targeted by end-2027. If FEST uses conventional equipment and partners fund capacity, more cash can support engineering and qualification. Extensive redesign or low yields would weaken the capital-light thesis and increase financing needs.

What risks could weaken the outlook?

Factorial is pre-revenue, technology-dependent, and still building public-company systems. A technical delay can postpone customer decisions, extend cash burn, raise dilution, and weaken manufacturing-partner leverage.

Which filing risk deserves special attention?

Management identified a March 31, 2026 material weakness involving system access, segregation of duties, reconciliations, and transaction review. Remediation was expected during 2027 at about $0.8 million. It raises execution risk amid de-SPAC accounting, complex equity instruments, and collaboration arrangements.

Why does the CGCT-to-FAC transition matter for valuation?

Factorial has no historical commercial revenue, so a DCF depends on sales timing, awarded-program probability, pricing, manufacturing cost, partner economics, capex, and dilution. Assumptions should be explicit and scenario ranges wide.

Which variables belong in a research model?

Near-term indicators are customer contracts, validation milestones, cash burn, capex, manufacturing yield, and diluted shares. The original trust is not a valuation anchor: $240.1 million was redeemed and closing gross proceeds were $112.1 million. Analysis must model Factorial’s operating future.

What is the key takeaway from Cartesian Growth Corporation III analysis?

Cartesian Growth Corporation III was the financing and listing bridge that took Factorial public. Its standalone story was a $276.0 million IPO, a trust reaching $285.869 million by March 2026, interest-driven earnings, and limited outside-trust liquidity. At the June 2026 combination, 83.5% of public shares redeemed and PIPE investors supplied most closing cash.

Factorial is technically promising but financially early. Large-format cells, OEM relationships, the 1,205-kilometer test, patents, and partner manufacturing support the case. Zero revenue, an $8.575 million Q1 2026 net loss, $6.120 million of operating cash use, unproven scale, dilution, and weak controls define the constraints.